Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer

NCT01434290 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT01434290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01434290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
May 20, 2022
Enrollment
255 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, psychosocial effects of cancer and its treatment, radiation toxicity, sexual dysfunction